HRP20192266T1 - Kompozicije i postupci za nekirurško liječenje ptoze - Google Patents
Kompozicije i postupci za nekirurško liječenje ptoze Download PDFInfo
- Publication number
- HRP20192266T1 HRP20192266T1 HRP20192266TT HRP20192266T HRP20192266T1 HR P20192266 T1 HRP20192266 T1 HR P20192266T1 HR P20192266T T HRP20192266T T HR P20192266TT HR P20192266 T HRP20192266 T HR P20192266T HR P20192266 T1 HRP20192266 T1 HR P20192266T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- oxymetazoline
- phenylephrine
- use according
- Prior art date
Links
- 206010015995 Eyelid ptosis Diseases 0.000 title claims 3
- 201000003004 ptosis Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012148 non-surgical treatment Methods 0.000 title 1
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 72
- 150000003839 salts Chemical class 0.000 claims 39
- 229960001528 oxymetazoline Drugs 0.000 claims 36
- 229960001802 phenylephrine Drugs 0.000 claims 15
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 4
- 210000000744 eyelid Anatomy 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
- B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (19)
1. Oksimetazolin, ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju ptoze kod subjekta, naznačen time što je oksimetazolin ili njegova farmaceutski prihvatljiva sol za primjenu na vanjsku površinu oka.
2. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa patentnim zahtjevom 1, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol osigurani kao farmaceutski prihvatljiva sol oksimetazolina.
3. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa patentnim zahtjevom 1, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol formulirani kao farmaceutska kompozicija koja sadrži najmanje 0,05 težinskih postotaka oksimetazolina u oftalmološki prihvatljivom nosaču.
4. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa patentnim zahtjevom 1, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol formulirani kao farmaceutska kompozicija koja sadrži najmanje 0,1 težinski postotak oksimetazolina u oftalmološki prihvatljivom nosaču.
5. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 1-4, gdje primjena rezultira u najmanje 10-postotnom povećanju u vertikalnoj razdvojenosti gornjih i donjih kapaka oka.
6. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 1-5, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol za primjenu u vidu jedne kapi.
7. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 1-6, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol za primjenu najmanje jednom dnevno.
8. Oksimetazolin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 1-7, gdje subjekt nema alergijsko stanje oka koje zahtjeva liječenje oka oksimetazolinom, nema otečenost očnog kapka, i nije podvrgnut refraktivnoj operaciji oka.
9. Alfa adrenergički agonist dugog djelovanja oksimetazolin, ili njegova farmaceutski prihvatljiva sol, i alfa adrenergički agonist kratkog djelovanja fenilefrin, ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju ptoze kod subjekta, naznačeni time što su oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin za primjenu na vanjsku površinu oka.
10. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa patentnim zahtjevom 9, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol formulirani kao farmaceutska kompozicija koja sadrži najmanje 0,05 težinskih postotaka oksimetazolina u oftalmološki prihvatljivom nosaču.
11. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa patentnim zahtjevom 9 ili 10, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol formulirani zajedno sa fenilefrinom kao farmaceutska kompozicija koja sadrži najmanje 0,1 težinski postotak oksimetazolina i najmanje 0,15 težinskih postotaka fenilefrina, opcionalno najmanje 0,25 težinskih postotaka fenilefrina, u oftalmološki prihvatljivom nosaču.
12. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 9-11, gdje primjena rezultira u najmanje 10-postotnom povećanju u vertikalnoj razdvojenosti gornjih i donjih kapaka oka.
13. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 9-12, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin za primjenu u vidu jedne kapi.
14. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 9-13, gdje su oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin za primjenu najmanje jednom dnevno.
15. Oksimetazolin ili njegova farmaceutski prihvatljiva sol i fenilefrin ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa bilo kojim od patentnih zahtjeva 9-14, gdje subjekt nema alergijsko stanje oka koje zahtjeva liječenje oka oksimetazolinom, nema otečenost očnog kapka, i nije podvrgnut refraktivnoj operaciji oka.
16. Farmaceutska kompozicija, koja sadrži alfa adrenergički agonist dugog djelovanja oksimetazolin ili njegovu farmaceutski prihvatljivu sol, alfa adrenergički agonist kratkog djelovanja fenilefrin ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, formulirana za topikalnu oftalmološku uporabu.
17. Farmaceutska kompozicija prema patentnom zahtjevu 16, naznačena time što su oksimetazolin ili njegova farmaceutski prihvatljiva sol prisutni u koncentraciji od najmanje 0,1 težinskog postotka.
18. Farmaceutska kompozicija prema patentnom zahtjevu 16 ili 17, naznačena time što su fenilefrin ili njegova farmaceutski prihvatljiva sol prisutni u koncentraciji od 0,15 do 1,5 težinskih postotaka, opcionalno najmanje 0,25 postotaka kada su oksimetazolin ili njegova farmaceutski prihvatljiva sol prisutni u koncentraciji od najmanje 0,1 težinskog postotka.
19. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 16-18, koja dalje sadrži agens odabran iz grupe koja se sastoji od adstringensa, antioksidanta, vitamina A, lubrikanta, plave boje, i bilo koje njihove kombinacije.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448949P | 2011-03-03 | 2011-03-03 | |
| US13/218,584 US20120225918A1 (en) | 2011-03-03 | 2011-08-26 | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| US13/270,577 US8357714B2 (en) | 2011-03-03 | 2011-10-11 | Compositions and methods for non-surgical treatment of ptosis |
| EP12709421.7A EP2680829B1 (en) | 2011-03-03 | 2012-02-24 | Compositions and methods for non-surgical treatment of ptosis |
| PCT/US2012/026496 WO2012118704A1 (en) | 2011-03-03 | 2012-02-24 | Compositions and methods for non-surgical treatment of ptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192266T1 true HRP20192266T1 (hr) | 2020-03-20 |
Family
ID=46753678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192266TT HRP20192266T1 (hr) | 2011-03-03 | 2019-12-17 | Kompozicije i postupci za nekirurško liječenje ptoze |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US20120225918A1 (hr) |
| EP (2) | EP2680829B1 (hr) |
| JP (1) | JP6106100B2 (hr) |
| KR (1) | KR101889392B1 (hr) |
| CN (1) | CN103501771B (hr) |
| AU (1) | AU2012223615B2 (hr) |
| BR (1) | BR112013022094A2 (hr) |
| CA (1) | CA2827285C (hr) |
| CY (1) | CY1122565T1 (hr) |
| DK (1) | DK2680829T3 (hr) |
| ES (1) | ES2750123T3 (hr) |
| HR (1) | HRP20192266T1 (hr) |
| HU (1) | HUE046740T2 (hr) |
| LT (1) | LT2680829T (hr) |
| MX (1) | MX345042B (hr) |
| PL (1) | PL2680829T3 (hr) |
| PT (1) | PT2680829T (hr) |
| RS (1) | RS59636B1 (hr) |
| RU (1) | RU2582392C2 (hr) |
| SG (1) | SG192801A1 (hr) |
| SI (1) | SI2680829T1 (hr) |
| WO (1) | WO2012118704A1 (hr) |
| ZA (1) | ZA201307262B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| WO2013041967A2 (en) | 2011-09-20 | 2013-03-28 | Altavista Instituto De Investigation Medica S.A.S | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| KR20160005351A (ko) * | 2013-05-06 | 2016-01-14 | 알러간, 인코포레이티드 | 조직 외상의 치료를 위한 알파 아드레날린 작용제 |
| CA2869060A1 (en) * | 2014-07-28 | 2016-01-28 | Queen's University At Kingston | Dosage forms and methods for diagnosing sympathetic nervous system dysfunction |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| EP3407976A4 (en) * | 2016-01-26 | 2019-07-17 | Levation Pharma Ltd. | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS |
| CN106726115B (zh) * | 2016-12-22 | 2023-01-20 | 上海交通大学医学院附属第九人民医院 | 一种眼睑功能矫正器 |
| CN106938039A (zh) * | 2017-03-29 | 2017-07-11 | 卢仁华 | 眼睑下垂的治疗药物 |
| WO2019204401A1 (en) * | 2018-04-19 | 2019-10-24 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| CN108635434A (zh) * | 2018-06-24 | 2018-10-12 | 吴安相 | 一种治疗眼睑下垂的侗族中药配方 |
| US20220033360A1 (en) * | 2018-11-26 | 2022-02-03 | Cellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| EP4138882A4 (en) * | 2020-04-23 | 2024-04-10 | Okogen Inc | TREATMENT OF VIRAL CONJUNCTIVITIS |
| WO2022187306A1 (en) | 2021-03-03 | 2022-09-09 | Voom, Llc | Compositions and methods for treatment of blepharitis |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1117588B (de) | 1960-09-30 | 1961-11-23 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates |
| US3670087A (en) * | 1970-10-16 | 1972-06-13 | Miles Lab | Method of lowering intraocular pressure |
| IE51421B1 (en) * | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| DE3227741A1 (de) | 1982-07-24 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung |
| FR2549015B1 (fr) * | 1983-07-13 | 1986-06-13 | Oreal | Ensemble compte-gouttes |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| WO1998047510A1 (fr) * | 1997-04-24 | 1998-10-29 | Taisho Pharmaceutical Co., Ltd. | Collyre |
| EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| US5885550A (en) * | 1998-07-02 | 1999-03-23 | Vallier; Deandra K. | Ophthalmic whitening solution |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
| WO2002024116A1 (en) * | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| JP2004509920A (ja) * | 2000-09-29 | 2004-04-02 | ボード オブ トラスティーズ オペレーティング ミシガン ステート ユニヴァーシティ | カテコールアミン医薬組成物および方法 |
| US7780976B2 (en) * | 2002-05-30 | 2010-08-24 | Eye Care And Cure, Asia | Apparatus and method for delivering controlled quantities of one or more agents to the eye |
| JP2005533076A (ja) * | 2002-06-20 | 2005-11-04 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | ムコ多糖及びプロピレングリコールを含む鼻用組成物 |
| US6806364B2 (en) | 2002-07-29 | 2004-10-19 | Ast Products, Inc. | Ophthalmic compositions |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US7022740B2 (en) | 2004-04-29 | 2006-04-04 | Leonard Mackles | Lubricious ophthalmic solutions |
| US7618615B2 (en) * | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| JP4942328B2 (ja) * | 2004-11-01 | 2012-05-30 | ロート製薬株式会社 | ビタミンｂ６類含有水性組成物 |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| JP4956981B2 (ja) * | 2005-01-05 | 2012-06-20 | 大正製薬株式会社 | オキシメタゾリン含有水性組成物 |
| KR20150017002A (ko) | 2006-03-17 | 2015-02-13 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물 |
| AU2007243334A1 (en) * | 2006-04-26 | 2007-11-08 | Aciex Therapeutics, Inc. | Compositions for the treatment and prevention of eyelid swelling |
| US8466203B2 (en) | 2006-12-06 | 2013-06-18 | David Choohyun Paik | Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds |
| JP2011503061A (ja) * | 2007-11-08 | 2011-01-27 | アーシエックス セラピューティックス， インコーポレイテッド | 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物 |
| ES2910374T3 (es) * | 2009-03-17 | 2022-05-12 | Nicox Ophthalmics Inc | Formulaciones oftálmicas de cetirizina y procedimientos de uso |
| CA2764477A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations, methods of manufacture, and methods of using same |
| CA2810267A1 (en) | 2010-08-06 | 2012-02-09 | Galderma Research & Development | Combination of compounds for treating or preventing skin diseases |
| JP6030067B2 (ja) | 2010-12-03 | 2016-11-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的クリーム組成物および使用法 |
| KR102058756B1 (ko) * | 2011-02-15 | 2020-01-22 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들 |
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| KR20150011807A (ko) | 2012-05-25 | 2015-02-02 | 질리어, 인크. | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| CA2951725C (en) | 2014-06-11 | 2022-06-07 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| EP3407976A4 (en) | 2016-01-26 | 2019-07-17 | Levation Pharma Ltd. | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
-
2011
- 2011-08-26 US US13/218,584 patent/US20120225918A1/en not_active Abandoned
- 2011-10-11 US US13/270,577 patent/US8357714B2/en active Active
-
2012
- 2012-02-24 WO PCT/US2012/026496 patent/WO2012118704A1/en active Application Filing
- 2012-02-24 PT PT127094217T patent/PT2680829T/pt unknown
- 2012-02-24 RU RU2013142602/15A patent/RU2582392C2/ru active
- 2012-02-24 AU AU2012223615A patent/AU2012223615B2/en active Active
- 2012-02-24 ES ES12709421T patent/ES2750123T3/es active Active
- 2012-02-24 LT LTEP12709421.7T patent/LT2680829T/lt unknown
- 2012-02-24 RS RS20191580A patent/RS59636B1/sr unknown
- 2012-02-24 BR BR112013022094A patent/BR112013022094A2/pt not_active Application Discontinuation
- 2012-02-24 CN CN201280011433.6A patent/CN103501771B/zh active Active
- 2012-02-24 JP JP2013556744A patent/JP6106100B2/ja active Active
- 2012-02-24 HU HUE12709421A patent/HUE046740T2/hu unknown
- 2012-02-24 SG SG2013062245A patent/SG192801A1/en unknown
- 2012-02-24 MX MX2013009597A patent/MX345042B/es active IP Right Grant
- 2012-02-24 DK DK12709421T patent/DK2680829T3/da active
- 2012-02-24 CA CA2827285A patent/CA2827285C/en active Active
- 2012-02-24 KR KR1020137026050A patent/KR101889392B1/ko active IP Right Grant
- 2012-02-24 PL PL12709421T patent/PL2680829T3/pl unknown
- 2012-02-24 EP EP12709421.7A patent/EP2680829B1/en active Active
- 2012-02-24 EP EP19199263.5A patent/EP3653205A3/en active Pending
- 2012-02-24 SI SI201231705T patent/SI2680829T1/sl unknown
- 2012-02-29 US US13/408,364 patent/US9018240B2/en active Active
-
2013
- 2013-09-27 ZA ZA2013/07262A patent/ZA201307262B/en unknown
-
2015
- 2015-02-18 US US14/625,099 patent/US9867808B2/en active Active
-
2017
- 2017-12-11 US US15/837,325 patent/US20180338953A1/en not_active Abandoned
-
2019
- 2019-09-20 US US16/577,262 patent/US10912765B2/en active Active
- 2019-11-07 CY CY20191101170T patent/CY1122565T1/el unknown
- 2019-12-17 HR HRP20192266TT patent/HRP20192266T1/hr unknown
-
2020
- 2020-06-04 US US16/892,645 patent/US20200360345A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/679,278 patent/US20220218669A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192266T1 (hr) | Kompozicije i postupci za nekirurško liječenje ptoze | |
| JP2014506927A5 (hr) | ||
| JP2010538011A5 (hr) | ||
| AR121843A2 (es) | Formulación oftálmica y método para mejorar la presbicia | |
| FI2887923T3 (fi) | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito | |
| WO2013184876A8 (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| WO2012103186A3 (en) | Androgen composition for treating an opthalmic condition | |
| AU2012307812A8 (en) | Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| BR112013003934A2 (pt) | depot de fosfolipídeos | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| WO2012063237A3 (en) | Buffered ophthalmic compositions and methods of use thereof | |
| CO6852073A2 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| HRP20231090T1 (hr) | Pripravci i metode sinergističkog tretmana glikokaliksa | |
| BR112015022044A2 (pt) | um método de proporcionar neutroproteção ocular | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| WO2014006635A3 (en) | Solid oral compositions of silodosin | |
| MX2015012716A (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. | |
| WO2013046059A3 (en) | Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose | |
| JP6449774B2 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 | |
| WO2015071299A3 (en) | Stable pharmaceutical glycylcycline compositions | |
| WO2014011949A3 (en) | Neuroprotective cb2 receptor agonists | |
| FR2976808B1 (fr) | Composition filmogene et son utilisation pour le traitement de l'herpes | |
| NZ709219A (en) | Gel compositions |